

Sacituzumab govitecan IMMU-132-01

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects



Other adjustments



Sacituzumab govitecan IMMU-132-01

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Therapeutic Indication: Treatment for adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease
 Experimental Arm: Sacituzumab govitecan
 Control Arm: Single arm (Phase I/II)

